Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 4Terminated 3Recruiting 3Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Melanoma 14Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Hematologic Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Xeroderma Pigmentosum 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uveal Melanoma 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Solid Tumor 1Sarcoma 1Neuroblastoma 1Multiple Myeloma 1Lymphoma 1Lymphatic Metastasis 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hemangiosarcoma 1Esophageal Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma 1

Interventions

Dexamethasone 45Bortezomib 19Lenalidomide 18Calcium Dobesilate 18Melphalan 16Cyclophosphamide 11pomalidomide 10daratumumab 9elotuzumab 8carfilzomib 8pembrolizumab 6ixazomib 6fludarabine phosphate 6dexamethasone acetate 6fludarabine 5dexamethasone 21-phosphate 5Filgrastim 5venetoclax 4selinexor 4auricularum 4Thalidomide 4Tacrolimus 4Peripheral Blood Stem Cell Transplantation 4Magnetic Resonance Spectroscopy 4liposomal doxorubicin 3Whole-Body Irradiation 3Vorinostat 3Nivolumab 3Mycophenolic Acid 3Leukapheresis 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Multiple Myeloma × Ipilimumab × Clear all
NCT03283046 2017-09-20

Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡